ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 243

Tracer Uptake from High Resolution Bone SPECT/CT Is Linked to Response in Rheumatoid Arthritis Patients

Yasser Abdelhafez1,2, Felipe Godinez3, Kanika Sood4, Rosalie Hagge2, Ramsey D Badawi2, Robert D Boutin2, Siba P. Raychaudhuri5 and Abhijit Chaudhari6, 1Nuclear Medicine Unit, South Egypt Cancer Institute, Assiut University, Assiut, Egypt, 2Radiology, Faculty of Medicine, University of California Davis, Sacramento, CA, 3Biomedical Engineering Department, King’s College London, London, United Kingdom, 4Rheumatology Section, Sacramento Veterans Affairs Medical Center, Sacramento, CA, 5Rheumatology, VA Sacramento Medical CenterUC Davis School of Medicine, Mather, CA, 6Radiology, UC Davis School of Medicine, Sacramento, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: computed tomography (CT) and rheumatoid arthritis (RA), Imaging

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Imaging of Rheumatic Diseases Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Tracer Uptake from High Resolution Bone SPECT/CT is Linked to Response in Rheumatoid Arthritis Patients.

Background/Purpose:

To evaluate the association between response to TNF-_ blockers and tracer uptake from dual-phase technetium-99m methylene diphosphonate (99mTc-MDP) bone scanning of the hands via a SPECT/CT system in patients with rheumatoid arthritis.

Methods:

Four patients with established rheumatoid arthritis (RA) were enrolled in this IRB-approved prospective pilot study. They were referred for performing bone scan prior to receiving TNF-_ blockers. Early blood pool (15 minutes after tracer injection, marker of hypervascularity) and delayed osseous phase (3 hours after the same injection, marker of osteoblastic activity) scans of the hands using 99mTc-MDP were performed using high-resolution SPECT/CT scanner. A special hand positioning device was designed and used during the scans. Second- to 5th metacarpo-phalangeal joints (MCP) were assessed qualitatively (normal vs. abnormal uptake) and quantitatively (by measuring the maximum counts). All counts were corrected to the background (defined as the median count from all normal joints). Qualitative and quantitative data were assessed against response.

Results:

After a median follow-up of 7.8 months (range: 6.9 Ð 21.7), two patients were considered responders and two were non-responders. A total of 32 joints were assessed. Early and delayed uptake in the 2nd to 5th MCP joints were abnormal in 7 joints, all belong to non-responders; while it was normal in 25 joints, 16 of them were in responders & 9 in non-responders; P = 0.007.

The median corrected counts from delayed scans were 0.92 (range: 0.49-1.49) in responders vs. 1.14 (range: 0.81-2.93) in non-responders; P = 0.002.

The median corrected counts from blood pool scans were 0.95 (range: 0.6-1.67) in responders vs. 1.1 (range: 0.55-2.29) in non-responders; P = 0.2.

Conclusion:

Delayed osseous uptake in metacarpophalangeal joints of rheumatoid arthritis patients, measured from 99mTc-MDP SPECT/CT, performed prior to treatment with TNF-_ blockers, was significantly higher in non-responders compared to responders, which might reflect higher baseline osteoblastic activity in non-responders.

Table 1: Ratio of the counts measured on 2nd to 4th metacarpophalangeal joints in responders and non-responders

Baseline SPECT/CT

Responders

Non-Responders

P

Blood Pool

Median (Range)

0.95 (0.6-1.67)

1.1 (0.55-2.29)

0.184

Mean±SD

0.98±0.32

1.29±0.57

Delayed Phase

Median (Range)

0.92 (0.49-1.49)

1.38±0.61

0.002

Mean±SD

0.88±0.25

1.14 (0.81-2.93)

Figure 1:


Disclosure: Y. Abdelhafez, Philips Healthcare, 2; F. Godinez, Philips Healthcare, 2; K. Sood, Philips Healthcare, 2; R. Hagge, Philips Healthcare, 2; R. D. Badawi, Philips Healthcare, 2; R. D. Boutin, Philips Healthcare, 2; S. P. Raychaudhuri, Philips Healthcare, 2; A. Chaudhari, Philips Healthcare, 2.

To cite this abstract in AMA style:

Abdelhafez Y, Godinez F, Sood K, Hagge R, Badawi RD, Boutin RD, Raychaudhuri SP, Chaudhari A. Tracer Uptake from High Resolution Bone SPECT/CT Is Linked to Response in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/tracer-uptake-from-high-resolution-bone-spectct-is-linked-to-response-in-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tracer-uptake-from-high-resolution-bone-spectct-is-linked-to-response-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology